Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xenon Pharmaceuticals Inc. - Common Shares
(NQ:
XENE
)
39.23
+1.00 (+2.62%)
Delayed Quote
Updated: 9:34 AM EST, Nov 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Xenon Pharmaceuticals Inc. - Common Shares
< Previous
1
2
3
4
5
Next >
Xenon to Present at Upcoming Investor Conferences
November 03, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Report Q3 2026 Financial Results on November 9, 2026
November 02, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 30, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
October 29, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law
September 23, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
September 21, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
September 17, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Present at Wells Fargo Healthcare Conference
September 03, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 28, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
August 26, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Reports Q2 2026 Financial Results and Provides Business Update
August 06, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Report Q2 2026 Financial Results on August 6, 2026
July 30, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 29, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Reports Q1 2026 Financial Results and Provides Business Update
May 07, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Report Q1 2026 Financial Results on May 7, 2026
April 30, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
April 19, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Present at Upcoming Investor Conferences
April 15, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
April 07, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
March 12, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
March 10, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Announces Proposed Public Offering
March 09, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
March 09, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
March 08, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
January 12, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
